CollPlant Biotechnologies Q2 Adj. EPS $(1.69) Misses $(0.24) Estimate, Sales $108.000K Miss $1.466M Estimate

CollPlant Biotechnologies (NASDAQ: CLGN) reported a Q2 adjusted EPS of $(1.69), missing the analyst estimate of $(0.24) by 604.17%. This represents a 26.52% improvement over the $(2.30) per share loss from the same quarter last year. The company's quarterly sales were $108,000, falling short of the $1.466 million estimate by 92.63% and marking a 39.66% decrease from $179,000 in the same period last year.